Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$423.65 USD

423.65
553,842

-6.17 (-1.44%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $423.84 +0.19 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 250)

Industry: Medical - Instruments

Zacks News

IDEXX (IDXX) Expands Test Menu for the Catalyst Platform

IDEXX's (IDXX) new Catalyst Pancreatic Lipase Test is likely to support veterinarians globally in diagnosing pancreatitis.

Why Is Idexx (IDXX) Up 5% Since Last Earnings Report?

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IDEXX (IDXX) Witnesses Rising Expenses, Currency Issues

IDEXX (IDXX) is being hurt by geopolitical instability, including the current war in Ukraine, which has affected supply chain operations globally.

IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed

IDEXX (IDXX) delivers better-than-expected earnings in the first quarter of 2024.

Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Idexx (IDXX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Idexx Laboratories (IDXX) Tops Q1 Earnings Estimates

Idexx (IDXX) delivered earnings and revenue surprises of 4.85% and 0.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Bruker's (BRKR) Balanced Segmental Growth, Innovation Aid

Bruker (BRKR) revenues continue to be driven by the strength of end markets, including academic, government and industrial.

Philips (PHG) Receives FDA Warning Letter Regarding CT Systems

Philips (PHG) receives a warning letter from the FDA in respect of a manufacturing plant in China regarding faults in the manufacturing of CT systems.

Seeking Clues to Idexx (IDXX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Idexx (IDXX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.

DexCom (DXCM) Q1 Earnings Beat, Strong CGM Demand Continues

DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

Revvity's (RVTY) New Launch to Boost Tuberculosis Testing

Revvity's (RVTY) latest offering is likely to provide a new and improved workflow to lower hands-on time and enable increased lab productivity.

CONMED (CNMD) Q1 Earnings & Revenues Surpass Estimates

CONMED's (CNMD) adjusted first-quarter earnings and revenues beat estimates on the back of strong U.S. and International markets as well as supply-chain improvement.

Veeva's (VEEV) AI Partner Program to Develop GenAI Solutions

Veeva (VEEV) announces the Veeva AI Partner Program, which is expected to provide partners assistance to combine Generative AI solutions with Veeva Vault applications.

West Pharmaceutical (WST) Q1 Earnings Beat, HVP Sales Weak

West Pharmaceutical's (WST) first-quarter results reflect a strong demand for non-COVID-19 products, especially HVP devices.

Integer (ITGR) Q1 Earnings and Revenues Top Estimates

Integer (ITGR) delivered earnings and revenue surprises of 1.79% and 0.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Penumbra's (PEN) New Launch to Enhance Blood Clot Removal

Penumbra's (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.

Reasons Why You Should Retain HealthEquity (HQY) Stock for Now

HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.

GE HealthCare's (GEHC) New Tie-Up to Boost Patient Outcomes

GE HealthCare's (GEHC) latest partnership is likely to benefit global healthcare systems by enhancing Elekta's RT offerings with its MIM Software medical imaging management solutions.

What Lies Ahead of IDEXX Laboratories (IDXX) in Q1 Earnings?

IDEXX Laboratories' (IDXX) first-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.

TMO vs. IDXX: Which Stock Is the Better Value Option?

TMO vs. IDXX: Which Stock Is the Better Value Option?

Idexx Laboratories (IDXX) Beats Stock Market Upswing: What Investors Need to Know

Idexx Laboratories (IDXX) concluded the recent trading session at $519.81, signifying a +0.99% move from its prior day's close.

Elevance Health (ELV) Brand Inks Deal to Better Serve Georgia

Elevance Health's (ELV) brand, Anthem Blue Cross and Blue Shield, collaborates to make the benefits of Piedmont's healthcare network available to its members across specific Georgia regions.

All You Need to Know About Idexx (IDXX) Rating Upgrade to Buy

Idexx (IDXX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?

Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.